1ST bags deal to consolidate market share
1st Available (ASX:1ST) has continued its quest to become the one online health service provider to rule them all – closing in on a deal which adds 130,000 users to the deck.
In a note to its shareholders today it said that it would move to acquire OzDocsOnline (ODO) for $150,000.
In exchange, 1ST will acquire an online booking service which is used by 130,000 patients and 8000 doctors.
OzDocsOnline is an online booking service which makes revenue by offering patients online access to their own doctor’s services including: online prescription requests; online access to pathology results; online consultations; and online referrals.
The doctors charge patients a flat fee to use each service.
In the 2016 financial year OzDocsOnline took in $310,000 in revenue, with $63,000 of that retained by the company while the rest was distributed to the doctors.
For 1ST, the deal is the latest of a string of deals completed in the last year including the acquisitions of DocAppointments, Clinic Connect, and GObookings.
1ST is attempting to build a hub to connect doctors and patients through a dedicated online portal and suite of apps, consolidating what is currently a fragmented market.
1ST managing director Klaus Bartosch said the deal made sense for both parties.
“Smaller players such as OzDocsOnline struggle to invest in their platforms to provide a future for their customers,” he said. “Not only does this acquisition provide a great future product roadmap for OzDocsOnline customers, but also new opportunities to help grow and manage their businesses.”
“It also helps expand our GP market share, growing our revenue base, consumer base and providing valuable IP (intellectual property).”
The deal is still subject to due diligence so it is not absolutely guaranteed at this stage – investors should seek professional financial advice before deciding whether or not to invest.
Short-term positions in small, early stage ASX companies,
with high potential and near term price catalysts.
Focusing on resource exploration, early-stage tech, and biotech.
Exceptional opportunities across a broad range of
early-stage growth sectors with strong management.
Seeking 1,000% plus returns across medium to long-term holds.
Longer-term positions in a variety of sectors.
Seeking strong management where traction is established and have entered into a growth phase.
S3 Consortium Pty Ltd (CAR No.433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information only. Any advice is general advice only. Neither your personal objectives, financial situation nor needs have been taken into consideration. Accordingly you should consider how appropriate the advice (if any) is to those objectives, financial situation and needs, before acting on the advice.
Conflict of Interest Notice
S3 Consortium Pty Ltd does and seeks to do business with companies featured in its articles. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this article. Investors should consider this article as only a single factor in making any investment decision. The publishers of this article also wish to disclose that they may hold this stock in their portfolios and that any decision to purchase this stock should be done so after the purchaser has made their own inquires as to the validity of any information in this article.
The information contained in this article is current at the finalised date. The information contained in this article is based on sources reasonably considered to be reliable by S3 Consortium Pty Ltd, and available in the public domain. No “insider information” is ever sourced, disclosed or used by S3 Consortium.